Home › Kanser sa Ovary › Massachusetts › Boston

Pag-aaral pangklinika para sa Kanser sa Ovary sa Boston, MA

Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Nagre-recruitPhase 1/2

Research Site, Boston

Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05417594

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Nagre-recruitPhase 2

Tufts Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Lahat ng edad · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564377

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Nagre-recruitPhase 1/2

Research Site, Boston

Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05797168

A Study of PHST001 in Advanced Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06840886

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 12 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Nagre-recruitPhase 2

Dana-Farber Cancer Institute - Oncology Department, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06760819

Distance-Based Exercise to Preserve Function and Prevent Disability

Nagre-recruit

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07059884

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 19 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06586957

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Nagre-recruit

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT05287451

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Nagre-recruitPhase 1

Research Site, Boston
Research Site, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05877599

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Nagre-recruitPhase 2

Site 0221 - Tufts Medical Center - PPDS, Boston
Site 0104 - Dana Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT05128825

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber / Harvard Cancer Center, Boston

Edad 18 pataas · Kababaihan · Na-update Set 25, 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute Brookline Avenue, Boston

Edad 18 pataas · Kababaihan · Na-update Set 24, 2026 · NCT04590326

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213791

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Nagre-recruitPhase 1/2

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07109726

Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

Nagre-recruitPhase 2

Tufts Medical Center, Boston

Edad 18 pataas · Kababaihan · Na-update Set 16, 2026 · NCT07718854

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Nagre-recruitPhase 2

Massachusetts General Hospital, Boston

Edad 18 hanggang 99 · Kababaihan · Na-update Set 15, 2026 · NCT07023627

A Study of Isoquercetin in People With Ovarian Cancer

Nagre-recruitPhase 2

Beth Israel Deaconess Medical Center (Data Collection Only), Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07303894

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Nagre-recruitPhase 2

Massachusetts General Hospital, Boston

Edad 18 pataas · Kababaihan · Na-update Set 14, 2026 · NCT06787612

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Nagre-recruitPhase 1/2

Tufts, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Nagre-recruitPhase 3

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Set 14, 2026 · NCT04575935

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Nagre-recruitPhase 1/2

Research Site, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05123482

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Nagre-recruitPhase 1

Beth Israel Deaconess Medical Center (BIDMC), Boston
Dana Farber Cancer Institute, Boston
Brigham and Women's Hospital, Boston

Edad 18 pataas · Kababaihan · Na-update Set 11, 2026 · NCT06964009

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT06293898

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Nagre-recruitPhase 1

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Set 3, 2026 · NCT07755436

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Nagre-recruitPhase 1/2

Dana-Farber Cancer Institute, Boston

12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06774963

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Nagre-recruitPhase 1

Normunity Investigational Site, Boston
Normunity Investigational Site, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Nagre-recruit

Beth Israel Deaconess Medical Center, Boston

Edad 35 hanggang 50 · Kababaihan · Na-update Ago 7, 2026 · NCT04251052

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05579366

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Nagre-recruitPhase 2

Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

Nagre-recruitPhase 1

Beth Israel Deaconess Medical Center, Boston

Edad 18 pataas · Kababaihan · Na-update Hul 23, 2026 · NCT03854110

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Kababaihan · Na-update Hul 6, 2026 · NCT07226427

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston
Brigham & Women's Hospital, Boston
Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
at 2 pa

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Nagre-recruitPhase 3

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Hul 2, 2026 · NCT06819007

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Nagre-recruitPhase 1/2

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Nagre-recruitPhase 2

GSK Investigational Site, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04641247

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Nagre-recruitPhase 1/2

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT06993844

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Nagre-recruit

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Hun 17, 2026 · NCT06543537

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Nagre-recruitPhase 1

Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Hun 16, 2026 · NCT06321484

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT04890613

Video Education With Result Dependent dIsclosure

Nagre-recruit

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT05225428

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Nagre-recruitPhase 1

Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update May 18, 2026 · NCT04701645

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update May 13, 2026 · NCT03686124

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Nagre-recruit

Massachusetts General Hospital-Cancer Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Abr 13, 2026 · NCT06710548

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Nagre-recruitPhase 1

Site 0104, Boston

Edad 18 pataas · Kababaihan · Na-update Abr 7, 2026 · NCT04516447

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Nagre-recruit

Dana Farber Cancer Institute, Boston

Edad 25 hanggang 50 · Kababaihan · Na-update Abr 6, 2026 · NCT04294927

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Nagre-recruitPhase 1/2

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 1, 2026 · NCT05735080

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Nagre-recruit

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Peb 19, 2026 · NCT04997096

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Kababaihan · Na-update Peb 3, 2026 · NCT06469281

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ene 14, 2026 · NCT06234423

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Nagre-recruitPhase 2

Massachusetts General Hospital, Boston

Edad 18 pataas · Kababaihan · Na-update Dis 23, 2025 · NCT06690775

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Nagre-recruitPhase 2

Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Kababaihan · Na-update Nob 5, 2025 · NCT06677190

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Nagre-recruitPhase 1/2

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2025 · NCT05941507

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

Nagre-recruitObservasyonal na pag-aaral

Massachusetts General Hospital, Boston

Edad 30 pataas · Kababaihan · Na-update Set 16, 2025 · NCT04794322

Comprehensive Outcomes for After Cancer Health

Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Dis 11, 2024 · NCT05349227

Pag-aaral para sa Kanser sa Ovary sa ibang lungsod

Iba pang pag-aaral sa Boston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.